A Randomized Controlled Trial Comparing the Efficacy and Safety of IDegLira Versus Basal-Bolus in Patients With Poorly Controlled Type 2 Diabetes and Very High HbA1c ≥9–15%: DUAL HIGH Trial

What is it about?

• In this randomized controlled trial of patients with type 2 diabetes and very high HbA1c > 9-15% (75-140.4 mmol/mol), the fixed-ratio combination (FRC) of basal insulin degludec and liraglutide resulted in similar improvement of glycemic control; but less hypoglycemia, less weight gain, and lower insulin requirements, compared to basal-bolus insulin regimen. • This study calls for a paradigm shift to change from the widely used basal-bolus insulin approach, to a simpler and more physiologic combination regimen of basal insulin and glucagon-like peptide-1 receptor agonist as the preferred option for patients with severe hyperglycemia and very high HbA1c >9-15% (75-140.4 mmol/mol).

Featured Image